Notes from the Field: Schedule I Substances Identified in Nootropic Gummies Containing Amanita muscaria or Other Mushrooms - Charlottesville, Virginia, 2023-2024

What is already known about this topic? Gummies listing the hallucinogenic mushroom Amanita muscaria or other unnamed mushrooms as ingredients have been marketed as “nootropics” (substances taken to enhance cognitive function). A. muscaria can cause hallucinations, agitation, gastrointestinal upset, and seizures. What is added by this report? During September 2023–June 2024, five persons required hospital evaluation after ingesting gummies labeled to contain A. muscaria. Five brands of gummies marketed as mushroom-containing nootropics were analyzed; three contained unlabeled Drug Enforcement Administration schedule I substances psilocybin and psilocin. What are the implications for public health practice? Health care providers and the public should be aware that edible products marketed as mushroom-containing nootropics might contain undisclosed ingredients and have been linked to severe illness. Persons who experience symptoms after consuming these products should seek immediate medical attention.